Ruben Bouma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ruben Bouma has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Anna Katrien Leontien Reyners
Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
2 shared publications - Mariken E. Stegmann
Department of Primary and Long-term Care, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
2 shared publications - Natasja J. H. Raijmakers
Department of Research & Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, the Netherlands
2 shared publications - Olaf P. Geerse
Medical Oncology, Amsterdam University Medical Center Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
2 shared publications Daan Brandenbarg
University Medical Center Groningen, Department of Primary and Long-Term Care, University of Groningen, The Netherlands
1 shared publication- Daan Brandenbarg
Department of Primary and Long-term Care, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
1 shared publication
Latest Publications
- 6 October 2026
- Published by Springer Nature in British Journal of Cancer
- p. 1-9
Trends in incidence and prevalence of patients living long-term with de novo metastatic incurable cancer: a retrospective cohort study
Background Therapeutic advances have improved the survival of incurable cancer patients, creating a growing population living long-term with incurable cancer. However, little is known about their epidemiological characteristics. We aimed to examine trends in annual incidence and prevalence among patients living long-term with de novo metastatic incurable cancer in the Netherlands and to describe additional relevant sociodemographic and clinical characteristics among patients diagnosed in recent years. Methods A population-based, retrospective cohort study using data from the Netherlands Cancer Registry was performed. Adults (≥18 years) diagnosed with de novo metastatic solid tumors in 2000–2021 who survived ≥2 years after their diagnosis were included. Annual incidence, prevalence, key demographic, and tumor characteristics were calculated. Results Annual incident cases of patients living long-term with de novo metastatic incurable cancer increased from 1298 (2000) to 5398 (2021), representing 12.0–22.6% of incurable cancer diagnoses. In February 2024, at least 18,466 patients in the Netherlands were living long-term with de novo metastatic incurable cancer (1 per 1000 inhabitants). Mean age was 64 years (SD 12), 59.4% were male, and 55.8% (n = 10,310) were alive 2- < 5 years after diagnosis, 31.0% (n = 5721) 5- < 10 years, and 13.2% (n = 2435) ≥ 10 years. The most common tumor types were prostate (35.6%), lung (20.2%), breast (14.4%), and colorectal cancer (6.3%). Conclusion Substantial increases in the incidence and prevalence were identified, reflecting a shift toward prolonged survival within the incurable cancer population. Greater awareness and research are needed to inform care for this emerging group.
- 6 October 2026
- Published by Springer Nature in British Journal of Cancer
- p. 1-9
Trends in incidence and prevalence of patients living long-term with de novo metastatic incurable cancer: a retrospective cohort study
Background Therapeutic advances have improved the survival of incurable cancer patients, creating a growing population living long-term with incurable cancer. However, little is known about their epidemiological characteristics. We aimed to examine trends in annual incidence and prevalence among patients living long-term with de novo metastatic incurable cancer in the Netherlands and to describe additional relevant sociodemographic and clinical characteristics among patients diagnosed in recent years. Methods A population-based, retrospective cohort study using data from the Netherlands Cancer Registry was performed. Adults (≥18 years) diagnosed with de novo metastatic solid tumors in 2000–2021 who survived ≥2 years after their diagnosis were included. Annual incidence, prevalence, key demographic, and tumor characteristics were calculated. Results Annual incident cases of patients living long-term with de novo metastatic incurable cancer increased from 1298 (2000) to 5398 (2021), representing 12.0–22.6% of incurable cancer diagnoses. In February 2024, at least 18,466 patients in the Netherlands were living long-term with de novo metastatic incurable cancer (1 per 1000 inhabitants). Mean age was 64 years (SD 12), 59.4% were male, and 55.8% (n = 10,310) were alive 2- < 5 years after diagnosis, 31.0% (n = 5721) 5- < 10 years, and 13.2% (n = 2435) ≥ 10 years. The most common tumor types were prostate (35.6%), lung (20.2%), breast (14.4%), and colorectal cancer (6.3%). Conclusion Substantial increases in the incidence and prevalence were identified, reflecting a shift toward prolonged survival within the incurable cancer population. Greater awareness and research are needed to inform care for this emerging group.
- Open Access
- 26 December 2025
- Published by SAGE Publications in Palliative Medicine
- Vol. 40 (2) , 217-227
Defining patients living long-term with incurable cancer: A modified hybrid Delphi study
Background: Therapeutic advances have significantly extended survival for certain groups of patients with incurable cancer, creating a growing population living long-term with incurable cancer. However, the absence of standardized definitions and terminology has contributed to limited recognition of this distinct group and their specific care needs. Aim: To achieve consensus on definitions and terminology for patients living long-term with incurable cancer by incorporating perspectives of patients, informal caregivers, healthcare professionals, and other relevant stakeholders. Design: A modified hybrid Delphi study, comprising focus groups and a three-round Delphi consensus process. Setting/participants: Three focus groups were conducted with patients ( n = 11), informal caregivers ( n = 4), and healthcare professionals ( n = 6). The multidisciplinary expert group comprised medical specialists ( n = 5), epidemiologists ( n = 3), and patient advocates ( n = 2). The Delphi study involved 78 panelists (73 unique respondents) divided into three subpanels: patients and informal caregivers ( n = 22), healthcare professionals ( n = 36), and other stakeholders ( n = 20). All participants were from the Netherlands. Results: We achieved 88% consensus on the terminology: Patients living long-term with incurable cancer. Consensus was reached on the definition (94%) for patients living for two or more years with: (1) incurable metastatic cancer, (2) incurable hematological malignancies, (3) incurable locally advanced cancer, or (4) patients with exceptionally long survival for their cancer type, despite not meeting the 2-year criterion. Conclusions: This modified hybrid Delphi study established the first consensus-based framework for patients living long-term with incurable cancer, providing essential groundwork for improved recognition and tailored care approaches for this population.
- 26 December 2025
- Published by SAGE Publications in Palliative Medicine
- Vol. 40 (2) , 217-227
Open AccessDefining patients living long-term with incurable cancer: A modified hybrid Delphi study
Background: Therapeutic advances have significantly extended survival for certain groups of patients with incurable cancer, creating a growing population living long-term with incurable cancer. However, the absence of standardized definitions and terminology has contributed to limited recognition of this distinct group and their specific care needs. Aim: To achieve consensus on definitions and terminology for patients living long-term with incurable cancer by incorporating perspectives of patients, informal caregivers, healthcare professionals, and other relevant stakeholders. Design: A modified hybrid Delphi study, comprising focus groups and a three-round Delphi consensus process. Setting/participants: Three focus groups were conducted with patients ( n = 11), informal caregivers ( n = 4), and healthcare professionals ( n = 6). The multidisciplinary expert group comprised medical specialists ( n = 5), epidemiologists ( n = 3), and patient advocates ( n = 2). The Delphi study involved 78 panelists (73 unique respondents) divided into three subpanels: patients and informal caregivers ( n = 22), healthcare professionals ( n = 36), and other stakeholders ( n = 20). All participants were from the Netherlands. Results: We achieved 88% consensus on the terminology: Patients living long-term with incurable cancer. Consensus was reached on the definition (94%) for patients living for two or more years with: (1) incurable metastatic cancer, (2) incurable hematological malignancies, (3) incurable locally advanced cancer, or (4) patients with exceptionally long survival for their cancer type, despite not meeting the 2-year criterion. Conclusions: This modified hybrid Delphi study established the first consensus-based framework for patients living long-term with incurable cancer, providing essential groundwork for improved recognition and tailored care approaches for this population.